NT1-O14B
Based on 2 publication(s) in Google Scholar
NT1-O14B is a tryptamine-derived lipidoid. NT1-O14B incorporates NT-lipidoid into BBB-impermeable lipid nanoparticles (LNPs), enabling the LNPs to cross the BBB. NT1-O14B enhances brain delivery via intravenous injection. NT1-O14B can be used in ischemic stroke research.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 98.43%
- CAS No.: 2739805-64-0
- 화학식: C40H68N2O4S4
- 분자량:769.24
-
보관:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) NT1-O14B
More
Biological Activity
제품 설명
In Vitro
NT1-014B 用于制备平均粒径在 140-170 nm 的 LNP3[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2739805-64-0
-
Appearance Viscous Liquid
-
분자량 769.24
-
화학식 C40H68N2O4S4
-
Color Colorless to light yellow
-
SMILES
O=C(CCN(CCC(OCCSSCCCCCCCCCC)=O)CCC1=CNC2=C1C=CC=C2)OCCSSCCCCCCCCCC
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Acta Biomater
Tuning the polyethylene glycol-lipid anchor length of lipid nanoparticles to enhance brain-targeted siRNA delivery. [Abstract]2025 Oct 11:S1742-7061(25)00762-7. PMID: 41083040 -
Mol Pharm
2026 May 4;23(5):2944-2954. PMID: 41931102
용액&용해도
In Vitro:
DMSO : 150 mg/mL (195.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 100 mg/mL (130.00 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocol
-
How to Select the Route of Administration for Mammals
Route-of-administration selection in mammals is a pharmacokinetic, pharmacodynamic, formulation, animal-welfare, and translational decision, not a default technical choice. The selected route should match the study goal: intravenous dosing is most useful when complete systemic exposure and rapid onset are required, oral dosing is most translational for orally intended medicines but is affected by absorption and first-pass metabolism, subcutaneous or intramuscular dosing can provide slower systemic exposure, and intraperitoneal dosing can be useful in rodent proof-of-concept studies but may have limited clinical translation. Published route-comparison studies show that the same compound can produce different exposure, onset, bioavailability, tissue distribution, and tolerability depending on route; therefore, route choice should be supported by pilot pharmacokinetic or pharmacodynamic evidence when the literature is insufficient. Unresolved questions include how to standardize route sel
순도&문서
-
Data Sheet (278 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ma F, et al. Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection. Sci Adv. 2020 Jul 24;6(30):eabb4429. [Content Brief]
[2]. Jia Y, et al. Nose-to-Brain Delivery of Circular RNA SCMH1-Loaded Lipid Nanoparticles for Ischemic Stroke Therapy. Adv Mater. 2025 Mar 27:e2500598. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 1.3000 mL | 6.4999 mL | 12.9998 mL | 32.4996 mL |
| 5 mM | 0.2600 mL | 1.3000 mL | 2.6000 mL | 6.4999 mL | |
| 10 mM | 0.1300 mL | 0.6500 mL | 1.3000 mL | 3.2500 mL | |
| 15 mM | 0.0867 mL | 0.4333 mL | 0.8667 mL | 2.1666 mL | |
| 20 mM | 0.0650 mL | 0.3250 mL | 0.6500 mL | 1.6250 mL | |
| 25 mM | 0.0520 mL | 0.2600 mL | 0.5200 mL | 1.3000 mL | |
| 30 mM | 0.0433 mL | 0.2167 mL | 0.4333 mL | 1.0833 mL | |
| 40 mM | 0.0325 mL | 0.1625 mL | 0.3250 mL | 0.8125 mL | |
| 50 mM | 0.0260 mL | 0.1300 mL | 0.2600 mL | 0.6500 mL | |
| 60 mM | 0.0217 mL | 0.1083 mL | 0.2167 mL | 0.5417 mL | |
| 80 mM | 0.0162 mL | 0.0812 mL | 0.1625 mL | 0.4062 mL | |
| 100 mM | 0.0130 mL | 0.0650 mL | 0.1300 mL | 0.3250 mL |